Minerva Neurosciences (NERV) Deferred Taxes (2016 - 2017)
Minerva Neurosciences' (NERV) quarterly Deferred Taxes came in at -$6.6 million in Q3 2017, down 286.27% on a QoQ basis from $3.6 million in Q2 2017.
Powered by 
Analysis
Minerva Neurosciences (NERV) Deferred Taxes (2016 - 2017) Analysis & Trends
Minerva Neurosciences (NERV) has 2 years of Deferred Taxes data on file, last reported at -$6.6 million in Q3 2017.
- Quarterly Deferred Taxes changed N/A year-over-year to -$6.6 million in Q3 2017, while the trailing twelve-month figure through Dec 2017 was -$2.5 million (changed N/A YoY) and the FY2021 annual result came in at -$1.8 million, changed N/A from the prior year.
- Deferred Taxes retreated to -$6.6 million in Q3 2017, from $3.6 million in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $3.6 million in Q2 2017 to a low of -$6.6 million in Q3 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | -6.83 Mn |
| Sep 30, 2017 | -6.65 Mn |
| Jun 30, 2017 | 3.57 Mn |
| Mar 31, 2017 | 530,298.00 |
| Dec 31, 2016 | -985,836.00 |